AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26721131 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with cognitive training (acupuncture at Baihui (GV 20), Fengchi (GB 20), Geshu (BL 17), and Fenglong (ST 40), once a day for 4 weeks)
Number of subjects: 60
Study 26721131 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training and conventional treatment (control group)
Number of subjects: 60
Study 26721131 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with cognitive training
Number of subjects: 60
Study 24018575 — intervention group
Group type: EXPERIMENTAL
Intervention: LACE training (20 sessions)
Number of subjects: 50
Study 24018575 — intervention group
Group type: COMPARATOR
Intervention: LACE training (less than 20 sessions)
Number of subjects: 50
Study 23376757 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational strategy (poster contest themed, 'Handwashing with Soap') in 23 NICHE primary schools
Number of subjects: 51
Study 23376757 — intervention group
Group type: COMPARATOR
Intervention: NICHE intervention (handwashing stations with treated water and soap)
Number of subjects: 51
Study 19224928 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AVDE after PCI
Number of subjects: 883
Study 19224928 — intervention group
Group type: COMPARATOR
Intervention: Patients without AVDE after PCI
Number of subjects: 883
Study 17456656 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 40 mg
Number of subjects: 805
Study 17456656 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Number of subjects: 805
Study 17456656 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg IV
Number of subjects: 805
Study 14971818 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilatation
Number of subjects: 104
Study 14971818 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy
Number of subjects: 104
Study 12482109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed estrogen therapy (Aerodiol) at a dose of 300 microg/day
Number of subjects: 0
Study 12482109 — intervention group
Group type: COMPARATOR
Intervention: Pulsed estrogen therapy (Aerodiol)
Number of subjects: 0
Study 9579493 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7% end‐tidal isoflurane
Number of subjects: 10
Study 9579493 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 10
Study 8080944 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 219
Study 8080944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelong coffee drinking
Number of subjects: 219
Study 8080944 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (heaviest drinkers)
Number of subjects: 219
Study 8080944 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharin intake
Number of subjects: 219
Study 8080944 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent consumption of carrots, spinach, and marrows
Number of subjects: 219
Study 8080944 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in a non-Mediterranean area
Number of subjects: 219
Study 8080944 — intervention group
Group type: EXPERIMENTAL
Intervention: Being born in a Mediterranean area
Number of subjects: 219
Study 8080944 — intervention group
Group type: EXPERIMENTAL
Intervention: High consumption of spices
Number of subjects: 219
Study 2676648 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (1.5 g twice daily)
Number of subjects: 43
Study 2676648 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg after evening meal)
Number of subjects: 43
Study 2676648 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate and Piroxicam
Number of subjects: 43
Study 1234807 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with Melphalan
Number of subjects: 149
Study 1234807 — intervention group
Group type: COMPARATOR
Intervention: Whole abdominal irradiation with additional treatment to the pelvis
Number of subjects: 149
Study 1234807 — intervention group
Group type: COMPARATOR
Intervention: Whole abdominal irradiation followed by strip irradiation to the entire abdomen
Number of subjects: 149
Study 30668137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Frailty Index (CFI) metrics - mean reaction time (RT) for total, first-half and second-half trials per condition
Number of subjects: 607
Study 30913134 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term type 1 diabetes mellitus (T1DM)
Number of subjects: 21
Study 30913134 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 28138315 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% CHO ingestion (CHOI)
Number of subjects: 9
Study 28138315 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% CHO mouth rinse (CHOR)
Number of subjects: 9
Study 28138315 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse (PLAR)
Number of subjects: 9
Study 28138315 — intervention group
Group type: COMPARATOR
Intervention: Placebo ingestion (PLAI)
Number of subjects: 9
Study 26602230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 37
Study 26602230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 23741991 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir 1400/100 mg with abacavir/lamivudine 600 mg/300 mg
Number of subjects: 101
Study 23741991 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg with abacavir/lamivudine 600 mg/300 mg
Number of subjects: 101
Study 23741991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 101
Study 23741991 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 101
Study 21532504 — intervention group
Group type: EXPERIMENTAL
Intervention: TC + endostar
Number of subjects: 126
Study 21532504 — intervention group
Group type: COMPARATOR
Intervention: TC + placebo
Number of subjects: 126
Study 19172543 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 30 microg + DRSP 3 mg
Number of subjects: 55
Study 19172543 — intervention group
Group type: COMPARATOR
Intervention: EE 30 microg + CMA 2 mg
Number of subjects: 55
Study 17927921 — intervention group
Group type: EXPERIMENTAL
Intervention: Monaural in-the-ear (ITE) hearing aid
Number of subjects: 34
Study 17927921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ITE hearing aids
Number of subjects: 34
Study 17927921 — intervention group
Group type: COMPARATOR
Intervention: Unilateral and bilateral hearing aids
Number of subjects: 34
Study 17927921 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening programme
Number of subjects: 34
Study 17927921 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiometric screening instrument
Number of subjects: 34
Study 15014936 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-delivered continence promotion program
Number of subjects: 0
Study 15014936 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study 11718974 — intervention group
Group type: EXPERIMENTAL
Intervention: Floor support surface
Number of subjects: 4
Study 11718974 — intervention group
Group type: COMPARATOR
Intervention: Overlay inflated support surface
Number of subjects: 4
Study 11718974 — intervention group
Group type: COMPARATOR
Intervention: Overlay deflated support surface
Number of subjects: 4
Study 11718974 — intervention group
Group type: COMPARATOR
Intervention: Low-air-loss inflated support surface
Number of subjects: 4
Study 11718974 — intervention group
Group type: COMPARATOR
Intervention: Foam mattress support surface
Number of subjects: 4
Study 9426671 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal ultrasonic-assisted tumescent liposuction (I-UATL)
Number of subjects: 28
Study 9426671 — intervention group
Group type: COMPARATOR
Intervention: Tumescent liposuction (TL)
Number of subjects: 28
Study 8387904 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 500 mg MK-886
Number of subjects: 36
Study 8387904 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 250 mg MK-886 every 8 hours
Number of subjects: 36
Study 3434603 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups with humor during hat-making activity
Number of subjects: 28
Study 3434603 — intervention group
Group type: COMPARATOR
Intervention: Groups without humor during bookmark-making activity
Number of subjects: 28
Study 29944553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM)
Number of subjects: 40
Study 29944553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM) in BCLP
Number of subjects: 40
Study 29944553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM) in UCLP
Number of subjects: 40
Study 29944553 — intervention group
Group type: COMPARATOR
Intervention: Control group (without NAM)
Number of subjects: 40
Study 27021556 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 89
Study 27021556 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 89
Study 24832000 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheters (IPCs)
Number of subjects: 0
Study 24832000 — intervention group
Group type: COMPARATOR
Intervention: Talc pleurodesis
Number of subjects: 0
Study 23775507 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 3314
Study 23775507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3314
Study 20367773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol HCl on-demand
Number of subjects: 35
Study 20367773 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily paroxetine
Number of subjects: 35
Study 19102862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1015
Study 19102862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 1015
Study 19102862 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1015
Study 19102862 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 1015
Study 17148516 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback + exercise
Number of subjects: 26
Study 17148516 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 26
Study 12643885 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission ST depression > or =1mm
Number of subjects: 918
Study 12643885 — intervention group
Group type: COMPARATOR
Intervention: No admission ST depression
Number of subjects: 918
Study 12643885 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent ST depression on discharge
Number of subjects: 918
Study 12643885 — intervention group
Group type: COMPARATOR
Intervention: No ST depression on discharge
Number of subjects: 918
Study 12643885 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-waves on discharge
Number of subjects: 918
Study 12643885 — intervention group
Group type: COMPARATOR
Intervention: No Q-waves on discharge
Number of subjects: 918
Study 11262895 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific dietary regimen based on comprehensive diagnosis of metabolic disorders (group 1)
Number of subjects: 207
Study 11262895 — intervention group
Group type: COMPARATOR
Intervention: Non-specific dietary regimen after limited metabolic evaluation (group 2)
Number of subjects: 207
Study 9322187 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of Cr as chromium picolinate, 2 times per day for 4 months
Number of subjects: 180
Study 9322187 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of Cr as chromium picolinate, 2 times per day for 4 months
Number of subjects: 180
Study 9322187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 8382969 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy (2 x 10(6) IU daily for a month, then every other day for 5 months)
Number of subjects: 26
Study 8382969 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) therapy
Number of subjects: 26
Study 8382969 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 26
Study 2873133 — intervention group
Group type: EXPERIMENTAL
Intervention: mesoridazine 400 mg/day
Number of subjects: 7
Study 2873133 — intervention group
Group type: EXPERIMENTAL
Intervention: thioridazine 800 mg/day
Number of subjects: 7
Study 2873133 — intervention group
Group type: COMPARATOR
Intervention: chlorpromazine 1800 mg/day
Number of subjects: 7
Study 2873133 — intervention group
Group type: EXPERIMENTAL
Intervention: mesoridazine or thioridazine
Number of subjects: 7
Study 2873133 — intervention group
Group type: EXPERIMENTAL
Intervention: mesoridazine
Number of subjects: 7
Study 2873133 — intervention group
Group type: COMPARATOR
Intervention: chlorpromazine
Number of subjects: 7
Study 2873133 — intervention group
Group type: EXPERIMENTAL
Intervention: thioridazine
Number of subjects: 7
Study 29382036 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A injections into four glands
Number of subjects: 90
Study 29382036 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A injections into three glands
Number of subjects: 90
Study 29382036 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A injections into two glands
Number of subjects: 90
Study 29382036 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT/A injections (overall)
Number of subjects: 90
Study 26606719 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-Based Collaborative Learning (CBCL)
Number of subjects: 64
Study 26606719 — intervention group
Group type: COMPARATOR
Intervention: Problem-Based Learning (PBL)
Number of subjects: 64
Study 24656867 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal manual treatment approach including analyzing treadmill with feedback, isokinetic dynamometric muscle strengthening, and balance retraining on dynamic balance platform
Number of subjects: 27
Study 24656867 — intervention group
Group type: COMPARATOR
Intervention: Standard care intervention for activities targeted to improve endurance, manual exercises of muscle strengthening, stretching exercises, gait, and balance exercises
Number of subjects: 27
Study 22239291 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 2695
Study 22239291 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 2695
Study 20605769 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Disclosure (Pennebaker Writing - PW)
Number of subjects: 40
Study 20605769 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Disclosure (King Writing - KW)
Number of subjects: 40
Study 20605769 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study 18443125 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD3100 therapy for 10 days
Number of subjects: 14
Study 18443125 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD3100 therapy
Number of subjects: 14
Study 18443125 — intervention group
Group type: COMPARATOR
Intervention: Baseline viruses from the X4 suppressor group
Number of subjects: 14
Study 18443125 — intervention group
Group type: COMPARATOR
Intervention: Baseline viruses from the X4 nonsuppressor group
Number of subjects: 14
Study 15994572 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg)
Number of subjects: 19
Study 15994572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12234230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ESWT (1000 mJ/mm² total dose, given weekly for 3 weeks)
Number of subjects: 160
Study 12234230 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6.0 mJ/mm² total dose)
Number of subjects: 160
Study 12234230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ESWT
Number of subjects: 160
Study 12234230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 9811522 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐12.5 (12.5 microg PT and FHA)
Number of subjects: 0
Study 9811522 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐25 (25 microg PT and FHA)
Number of subjects: 0
Study 9811522 — intervention group
Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine (DPT)
Number of subjects: 0
Study 9811522 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccines (DTaP‐12.5 and DTaP‐25)
Number of subjects: 0
Study 9811522 — intervention group
Group type: COMPARATOR
Intervention: DTP
Number of subjects: 0
Study 7581587 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen administration
Number of subjects: 0
Study 7581587 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen administration with progestogen co-medication
Number of subjects: 0
Study 3055672 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg decaris weekly (150 mg for 2 successive days) for 15 months (group 3)
Number of subjects: 92
Study 3055672 — intervention group
Group type: COMPARATOR
Intervention: 300 mg decaris weekly (150 mg for 2 successive days) for 1 month (group I)
Number of subjects: 92
Study 3055672 — intervention group
Group type: COMPARATOR
Intervention: 300 mg decaris weekly (150 mg for 2 successive days) for 3 months (group 2)
Number of subjects: 92
Study 30183531 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning in artificial saliva (SAGF) for seven days at 37°C
Number of subjects: 30
Study 30183531 — intervention group
Group type: COMPARATOR
Intervention: Conditioning in air for seven days at 37°C
Number of subjects: 30
Study 30183531 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic and static three-point flexural testing
Number of subjects: 30
Study 30183531 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-flexural test (MFT)
Number of subjects: 30
Study 30183531 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO flexural test (IFT)
Number of subjects: 30
Study 28357715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0
Study 28357715 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 28357715 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 28357715 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 28357715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho‐Cyclen®
Number of subjects: 0
Study 25987260 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bicarbonate level
Number of subjects: 2628
Study 25987260 — intervention group
Group type: COMPARATOR
Intervention: Serum bicarbonate level (quartile with lowest bicarbonate ≤21 mEq/L)
Number of subjects: 2628
Study 24282774 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 44
Study 24282774 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 44
Study 21296247 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoke exposure (PSE)
Number of subjects: 385
Study 21296247 — intervention group
Group type: COMPARATOR
Intervention: Non-passive smoke exposure (non-PSE)
Number of subjects: 385
Study 19167012 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment resolution (STR) assessed immediately after primary PCI
Number of subjects: 28
Study 19167012 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum single-lead ST-segment elevation assessed immediately after primary PCI
Number of subjects: 28
Study 16754727 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/d)
Number of subjects: 19747
Study 16754727 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene (60 mg/d)
Number of subjects: 19747
Study 15006009 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patches delivering 25 microg fentanyl/h (TTS‐fentanyl)
Number of subjects: 26
Study 15006009 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol and codeine (P/C) 500 mg paracetamol and 30 mg codeine four times per day
Number of subjects: 26
Study 15006009 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS‐fentanyl)
Number of subjects: 26
Study 15006009 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol and codeine (P/C)
Number of subjects: 26
Study 11305684 — intervention group
Group type: EXPERIMENTAL
Intervention: N,N-dimethylglycine
Number of subjects: 37
Study 11305684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9039618 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic susceptibility contrast (DSC) MRI
Number of subjects: 32
Study 9039618 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 32
Study 8159516 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial agents for otitis media
Number of subjects: 0
Study 8159516 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics for sinusitis
Number of subjects: 0
Study 8159516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalosporins or macrolides
Number of subjects: 0
Study 8159516 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 0
Study 3884719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3884719 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 gm aspirin
Number of subjects: 30
Study 3884719 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 gm aspirin
Number of subjects: 30
Study 29341103 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27470430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 10 µg delivered dose (Laboratorios Liconsa, Spain)
Number of subjects: 30
Study 27470430 — intervention group
Group type: COMPARATOR
Intervention: Spiriva HandiHaler(®) (Boehringer Ingelheim Pharma GmbH & Co KG, Germany)
Number of subjects: 30
Study 25826731 — intervention group
Group type: COMPARATOR
Intervention: CBT-MI alone
Number of subjects: 0
Study 25826731 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-MI-SP (with support person)
Number of subjects: 0
Study 22978405 — intervention group
Group type: EXPERIMENTAL
Intervention: VigRX Plus (VXP)
Number of subjects: 78
Study 22978405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 22978405 — intervention group
Group type: COMPARATOR
Intervention: VigRX Plus (VXP) and Placebo
Number of subjects: 78
Study 20100135 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 weeks of group exercise consisting of aerobic training and non-aerobic weight-lifting
Number of subjects: 48